Cytarabine
Cold Chain RequiredFDA Approved, EMA Approved
Contents
Description
Cytarabine is an antimetabolite chemotherapy agent that interferes with DNA synthesis. It is a standard component of induction and consolidation therapy for acute myeloid leukemia, including inherited forms. The drug is converted intracellularly to its active triphosphate form.
Indications & Therapeutic Use
acute myeloid leukemia, acute lymphocytic leukemia, chronic myeloid leukemia blast phase, meningeal leukemia
Global Availability (10 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Buy / Source Cytarabine — GNH India
139 matching products available through GNH India. Select a product to view details and request a quote on the GNH India website.
Alexan
EU
Ara-Cell
EU
Aracytin
EU
Aracytine
EU
Citabion
EU
Citaloxan
EU
Citarabin Accord
EU
Citarabina Accord
EU
Products and ordering are fulfilled by GNH India. You will be redirected to www.gnhindia.com.
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Cytarabine
| Generic Name | cytarabine |
| Brands | 1 brand available |
| Active Ingredient | cytarabine |
| Drug Class | acute myeloid leukemia |
| Manufacturer | Pfizer |
| Dosage Forms | IV infusion, 20mg/mL, 100mg/mL; Intrathecal injection, 50mg/mL |
| Medical Code | L01BC01 |
| Orphan Status | No |
| Cold Chain | Required |
| Lead Time | 3 days |
| Reg. Status | FDA Approved, EMA Approved |
| Clinical Trial | NCT00002798 |
| Countries | 10 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations11 Validated Nodes